Evidence map›Paper›PMID 42448430›Full record

ArticleJournal for immunotherapy of cancer2026

Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity.

Nicole Oelgarth, Kea Martin, Fabian Junker, Clara Serger, Caoimhe Herr, Mélanie Buchi, Lilian Gremlich, Irene Fusi, Jonas Fürst, Petra Herzig and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Nicole Oelgarth *Department of Biomedicine, University Hospital Basel, Basel, Switzerland.ORCID http://orcid.org/0009-0003-3968-4104
Kea Martin *Bright Peak Therapeutics, Allschwil, Switzerland.
Fabian JunkerBright Peak Therapeutics, Allschwil, Switzerland.ORCID http://orcid.org/0000-0003-4548-9842
Clara SergerDepartment of Biomedicine, University Hospital Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0002-2236-7300
Caoimhe HerrBright Peak Therapeutics, Allschwil, Switzerland.
Mélanie BuchiDepartment of Biomedicine, University Hospital Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0001-9958-9748
Lilian GremlichBright Peak Therapeutics, Allschwil, Switzerland.
Irene FusiDepartment of Biomedicine, University Hospital Basel, Basel, Switzerland.
Jonas FürstDepartment of Biomedicine, University Hospital Basel, Basel, Switzerland.
Petra HerzigDepartment of Biomedicine, University Hospital Basel, Basel, Switzerland.
Philipp MoosmannBright Peak Therapeutics, Allschwil, Switzerland.
Viola Heinzelmann-SchwarzDepartment of Gynecology and Obstetrics, University Hospital Basel, Basel, Switzerland.
Kirsten D MertzInstitute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Robert RosenbergDepartment of Visceral Surgery, Cantonal Hospital Basel-Landschaft, Liestal, Switzerland.
Karin SchaeubleDepartment of Biomedicine, University Hospital Basel, Basel, Switzerland.
Jean-Philippe CarralotBright Peak Therapeutics, Allschwil, Switzerland.
Thuy T LuuDepartment of Biomedicine, University Hospital Basel, Basel, Switzerland.
Bertolt KreftBright Peak Therapeutics, Allschwil, Switzerland.
Vijaya PattabiramanBright Peak Therapeutics, Allschwil, Switzerland alfred.zippelius@usb.ch vpattabiraman@brightpeaktx.com.
Alfred ZippeliusDepartment of Biomedicine, University Hospital Basel, Basel, Switzerland alfred.zippelius@usb.ch vpattabiraman@brightpeaktx.com.ORCID http://orcid.org/0000-0003-1933-8178

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors have revolutionized cancer therapy, yet a substantial proportion of patients exhibit primary or acquired resistance. Immunocytokines offer a strategy to enhance antitumor immunity by delivering cytokine signals selectively to the tumor microenvironment. Here, we describe the immunoconjugate anti-programmed cell death protein 1 (PD-1)-interleukin (IL)-18 (aPD1-IL18

methodsaPD1-IL18

resultsIn vitro, PD-1 engagement enhanced functional IL-18 activity, preserving interferon (IFN)-γ secretion even under IL-18BP pressure. In MC38 tumors, aPD1-IL18

conclusionsaPD1-IL18

Indexed as

Immune Checkpoint InhibitorsImmunoconjugatesInterleukin-18NeoplasmsProgrammed Cell Death 1 ReceptorAnimalsCD8-Positive T-LymphocytesHumansMiceMice, TransgenicTumor MicroenvironmentIL18 protein, humanImmune Checkpoint InhibitorsImmunoconjugatesInterleukin-18PDCD1 protein, humanProgrammed Cell Death 1 ReceptorAntibodyCytokineImmune Checkpoint InhibitorImmunotherapy

Identifiers

PMID42448430
PMCPMC13374488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.